{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:28:34Z","timestamp":1791260914867,"version":"4.1.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T00:00:00Z","timestamp":1275523200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0010952","type":"journal-article","created":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T20:44:08Z","timestamp":1275597848000},"page":"e10952","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":111,"title":["Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Na\u00efve Subjects in the CASTLE Study"],"prefix":"10.1371","volume":"5","author":[{"given":"Max","family":"Lataillade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chiarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Schnittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donnie","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Simen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Egholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kozal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors.","volume":"74","author":"F Sanger","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nm0796-753","article-title":"Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.","volume":"2(7)","author":"MJ Kozal","year":"1996","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2144\/03341dd05","article-title":"Quantitative detection of low-copy-number mRNAs differing at single nucleotide positions.","volume":"34(1)","author":"J Stenman","year":"2003","journal-title":"BioTechniques"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature03959","article-title":"Genome sequencing in microfabricated high-density picolitre reactors.","volume":"437(7057)","author":"M Margulies","year":"2005","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/nar\/gkm435","article-title":"DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations.","volume":"35","author":"C Hoffmann","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"ref6","first-page":"S150","article-title":"Comparison of traditional plasmid-based clonal sequencing to 454 ultra-deep sequencing for HIV clinical isolates with reverse transcriptase (RT) mutations at K65R and L74V.","volume":"12","author":"R Lanier","year":"2007","journal-title":"Antiviral Therapy"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1469-0691.2008.02687.x","article-title":"Drug Resistant HIV.","volume":"15","author":"MJ Kozal","year":"2009","journal-title":"Clinical Microbiology and Infection"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.aids.0000216370.69066.7f","article-title":"Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.","volume":"20","author":"S Palmer","year":"2006","journal-title":"AIDS"},{"key":"ref9","first-page":"672","article-title":"Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.","volume":"201(5)","author":"EK Halvas","year":"2010","journal-title":"J Infect Dis"},{"key":"ref10","first-page":"662","article-title":"Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.","volume":"201(5)","author":"R Paredes","year":"2010","journal-title":"J Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1086\/528802","article-title":"Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.","volume":"197(6)","author":"DR Kuritzkes","year":"2008","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy.","volume":"5(7)","author":"JA Johnson","year":"2008","journal-title":"PLoS Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/595703","article-title":"Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.","volume":"48(2)","author":"KJ Metzner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/596736","article-title":"Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral Treatment\u2013Naive patients significantly impact treatment outcomes.","volume":"199(5)","author":"BB Simen","year":"2009","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/QAD.0b013e3283034953","article-title":"Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.","volume":"22(12)","author":"O Peuchant","year":"2008","journal-title":"AIDS"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1086\/650001","article-title":"Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.","volume":"50(4)","author":"MR Jakobsen","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.","volume":"4(3)","author":"DE Bennett","year":"2009","journal-title":"PLoS ONE"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.","volume":"372(9639)","author":"JM Molina","year":"2008","journal-title":"LANCET"},{"key":"ref19","article-title":"Atazanavir\/Ritonavir vs Lopinavir\/Ritonavir in Antiretroviral-Na\u00efve HIV-1-Infected Patients: CASTLE 96 Week Efficacy and Safety.","author":"JM Molina","year":"2008"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"P180","DOI":"10.1186\/1758-2652-11-S1-P180","article-title":"Impact of HIV viral diversity and baseline resistance on treatment outcomes and the emergence of resistance: The CASTLE study 48-week results.","volume":"11","author":"M Lataillade","year":"2008","journal-title":"Journal of the International AIDS Society"},{"key":"ref21","first-page":"A135","article-title":"The CASTLE Study 48 week results: The impact of HIV subtypes and baseline resistance on treatment outcomes and the emergence of resistance.","volume":"13","author":"M Lataillade","year":"2008","journal-title":"Antiviral Therapy"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/jmv.10550","article-title":"Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.","volume":"72(1)","author":"AG Marcelin","year":"2004","journal-title":"J Med Virol"},{"key":"ref23","first-page":"298","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database.","volume":"31","author":"SY Rhee","year":"2003"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy.","volume":"5(7)","author":"JA Johnson","year":"2008","journal-title":"PLoS Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jviromet.2007.05.009","article-title":"Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.","volume":"145","author":"H Vermeiren","year":"2007","journal-title":"J Virol Methods"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/01.qai.0000219776.27798.e7","article-title":"External validation of atazanavir\/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.","volume":"42","author":"AG Marcelin","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref27","first-page":"S97","article-title":"Evaluation of resistance patterns in treatment-naive subjects with virological failure on atazanavir- or atazanavir\/ritonavir-containing regimens.","volume":"11","author":"D McGrath","year":"2006","journal-title":"Antiviral Therapy"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/01.aids.0000218548.77457.76","article-title":"Effect of baseline protease genotype and phenotype on HIV response to atazanavir\/ritonavir in treatment-experienced patients.","volume":"20","author":"LK Naeger","year":"2006","journal-title":"AIDS"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.","volume":"369","author":"B Clotet","year":"2007","journal-title":"LANCET"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1086\/651136","article-title":"Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.","volume":"201(7)","author":"KJ Metzner","year":"2010","journal-title":"J Infect Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QAI.0b013e31814258c0","article-title":"Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.","volume":"46","author":"ES Svarovskaia","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref32","article-title":"Virologic Success of Different Strategies for Initial Antiretroviral Therapy Regimens Is Predicted by the Type and Detection Level of Minor Drug Resistant Variants Detected by Ultra Deep Sequencing: The CPCRA 058 (FIRST) Study.","author":"K Huppler-Hullsiek","year":"2008"},{"key":"ref33","first-page":"A43","article-title":"Pre-existing low levels of K103N HIV-1 RT mutation above a threshold is associated with virologic failure in treatment na\u00efve patients undergoing EFV-containing antiretroviral treatment.","volume":"14","author":"DD Goodman","year":"2009","journal-title":"Antiviral Therapy"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e6079","DOI":"10.1371\/journal.pone.0006079","article-title":"Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use.","volume":"4(6)","author":"T Le","year":"2009","journal-title":"PLoS ONE"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1101\/gr.6468307","article-title":"Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance.","volume":"17(8)","author":"C Wang","year":"2007","journal-title":"Genome Res"},{"key":"ref36","article-title":"Statistical Methods for Rates and Proportions","author":"L Fleiss Joseph","year":"1981"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0010952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T21:41:38Z","timestamp":1635457298000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0010952"}},"subtitle":[],"editor":[{"given":"Lishomwa C.","family":"Ndhlovu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,6,3]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,6,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0010952","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,3]]}}}